Cipla Ltd.'s consolidated net profit rose 18% in the first quarter of the current financial year, meeting analysts' estimates.
The drugmaker posted a profit of Rs 1,175 crore in the quarter-ended June, according to an exchange filing on Friday. That compares with the Rs 1,120.4-crore consensus estimate of analysts tracked by Bloomberg.
Cipla Q1 FY25 Highlights (Consolidated, YoY)
Revenue up 6% to Rs 6,694 crore versus Rs 6,329 crore (Bloomberg estimate: Rs 6,795.5 crore).
Ebitda up 15% to Rs 1,1716 crore versus Rs 1,494 crore (Estimate: Rs 1,671.3 crore).
Margin expands to 25.6% versus 24% (Estimate: 24.6%).
Net profit up 18% to Rs 1,175 crore vs Rs 998 crore (Estimate: Rs 1,120.4 crore).
The India branded prescription business grew at a healthy rate of 10% year-on-year. Overall, One India growth was offset by weakness in trade generics business owing to distribution model change.
All-time high revenue at $250 million, up by 13% year-on-year, supported by traction in differentiated portfolio.
Momentum continues with revenue growth at 19% in local currency terms. Prescription business ranked one in the market.
R&D investments stand at Rs 353 crore or 5.3% of sales, higher by 1% YoY, driven by product filings and developmental efforts.
Net cash position of Rs 8,449 crore. Debt primarily includes lease liabilities and working capital requirements.
Patalganga and Kurkumbh facilities were classified as ‘Voluntary Action Indicated' by US FDA.
Shares of Cipla were trading 5.93% higher at Rs 1,589 apiece on the NSE, as compared to a 1.8% advance in the benchmark NSE Nifty 50.
Watch LIVE TV, Get Stock Market Updates, Top Business, IPO and Latest News on NDTV Profit.
